Shots:
- QIAGEN signed a definitive agreement to acquire Parse Biosciences, expanding QIAGEN’s sample technologies portfolios and digital insights
- Under the agreement, QIAGEN will acquire Parse Biosciences for $225M upfront cash plus up to $55M in milestone payments. The deal is expected to close in December 2025, and Parse is projected to add $40M in sales to QIAGEN in 2026 (2% growth)
- Furthermore, the acquisition is expected to dilute 2026 adjusted EPS by $0.04 and become accretive in 2028
Ref: QIAGEN | Image: Parse Biosciences | Press Release
Related News:- Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
